[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550651":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":78,"collaborators":10,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":10,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":93,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":105,"whyStopped":10,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Zhujiang Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient with hepatocellular carcinoma",null,"Patient with hepatocellular carcinoma who can undergo radical resection",[13],"Diagnostic Test: circulating tumor cell DNA detection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","circulating tumor cell DNA detection","circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma",[9],[21],{"name":22,"affiliation":23,"role":24},"Mingxin Pan, Prof.","Southern Medical University","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+8618928918216","pmxwxy@sohu.com",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Jianan Feng","13825522877","972929217@qq.com",[35,52,57,70],{"facility":36,"status":10,"city":37,"state":38,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Shunde Hospital of Southern Medical University","Foshan","Guangdong","China","CN",{"type":42,"coordinates":43},"Point",[44,45],113.13148,23.02677,{"lat":45,"lon":44},[48,51],{"name":49,"role":27,"phone":50,"phoneExt":10,"email":10},"Weidong Wang, Prof.","13702835586",{"name":49,"role":24,"phone":10,"phoneExt":10,"email":10},{"facility":53,"status":10,"city":37,"state":38,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":54,"geoPoint":56,"contacts":10},"The Sixth Affiliated Hospital of South China University of Technology",{"type":42,"coordinates":55},[44,45],{"lat":45,"lon":44},{"facility":58,"status":10,"city":59,"state":38,"zip":60,"country":39,"countryCode":40,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Zhujiang Hospital of Southern Medical University","Guangzhou","510220",{"type":42,"coordinates":62},[63,64],113.25,23.11667,{"lat":64,"lon":63},[67,68,69],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"facility":71,"status":10,"city":72,"state":38,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Sun Yat-sen University Cancer Center","Guanzhou",{"type":42,"coordinates":74},[75,76],113.37117,23.06828,{"lat":76,"lon":75},{"type":79,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100550651","compare-the-accuracy-of-ctdna-mrd-and-mvi-result-in-predicting-postoperative-recurrence-of-hepatocellular-carcinoma-100550651",false,"NCT06449846","Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma","Compare the Accuracy of Circulating Tumor DNA Longitudinal Monitoring Minimal Residual Disease and Microvascular Invasion Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Male or female patients aged 18-75 years;\n2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0\u002F stage A\u002Fstage B, eligible for radical surgery;\n3. ECOG physical status score is 0-1;\n4. Child-Pugh score is 5-6 points (Level A);\n5. Not received any anti-tumor therapy;\n6. Laboratory tests were at normal levels within 7 days before enrollment.\n\nExclusion Criteria:\n\n1. Patient can't provide blood samples for ctDNA testing;\n2. Patient with two or more types of tumors at the same time;\n3. Non-primary liver lesions;\n4. Pregnant or lactating women;\n5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;\n6. Patient with serious heart disease;\n7. Other conditions deemed unsuitable for inclusion by the researcher.","ALL","18 Years","75 Years",{"count":91,"type":92},152,"ESTIMATED","2 Years","OBSERVATIONAL","The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy. At the same time, to explore the relationship among the two methods of predicting recurrence of hepatocellular carcinoma, postoperative adjuvant therapy and postoperative recurrence, this study further confirmed the effectiveness of ctDNA-MRD longitudinal monitoring model in monitoring postoperative recurrence of hepatocellular carcinoma and guiding treatment.",[97,98,99],"Hepatocellular Carcinoma Resectable","Surgery","Recurrence",[101,102,103,104],"Hepatocellular Carcinoma","Circulating Tumor DNA","Minimal Residual Disease","Microvascular Invasion","NOT_YET_RECRUITING","2024-06-03",{"date":108,"type":109},"2024-06-10","ACTUAL",{"date":111,"type":92},"2024-06-01",{"date":113,"type":92},"2026-12-31",{"name":5,"class":6},4]